No Red Tape For Addiction Treatment Act
Sponsored By: Senator Maggie Hassan
Introduced
Summary
This bill would require State Medicaid programs to cover at least one formulation of every medication and biological product for treating opioid use disorder without prior authorization or limits on dosage. It would also require coverage of long‑acting injectable forms when available and would not stop States from keeping a formulary that meets existing federal rules.
Show full summary
- People with opioid use disorder and their families would face fewer paperwork hurdles to start or continue medication‑assisted treatment because at least one form of each drug must be covered with no prior authorization and no dosage caps.
- State Medicaid programs would need to change their plans or waivers to meet the new coverage rule. The requirement would apply to medical assistance provided on or after 1 year after enactment, and States that need new legislation get a limited implementation delay.
- The Medicaid and CHIP Payment and Access Commission (MACPAC) would have to report to Congress within 1 year on how States use utilization management controls for medication‑assisted treatment, including dosing limits, age limits, counseling requirements, psychological screening, and the administrative burden on clinicians and providers.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Easier Medicaid access to OUD medicines
If enacted, this bill would require State Medicaid plans and waivers to cover at least one formulation of every drug or biological product used to treat opioid use disorder without prior authorization or dosage limits. If a long‑acting injectable form exists for a drug, the state would have to cover that injectable option. The bill would not stop States from using formularies that follow existing federal rules. These changes would apply to medical assistance provided on or after 1 year after enactment. If a State plan requires State legislation to comply, the plan would not be treated as out of compliance until the first day of the first calendar quarter beginning after the close of the first regular session of the State legislature that begins after enactment; for 2‑year sessions, each year of the session is treated as a separate regular session.
Sponsors & CoSponsors
Sponsor
Maggie Hassan
NH • D
Cosponsors
James Justice
WV • R
Sponsored 12/17/2025
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in